LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles.
Sign Up to like articles & get recommendations!
Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial.
3099Background: Stratum D of the INSIGHT study investigates the feasibility and safety of s.c. application of IMP321 (eftilagimod alpha) combined with the PD-L1 inhibitor avelumab in advanced stage... Click to show full abstract
3099Background: Stratum D of the INSIGHT study investigates the feasibility and safety of s.c. application of IMP321 (eftilagimod alpha) combined with the PD-L1 inhibitor avelumab in advanced stage...
Share on Social Media:
  
        
        
        
Sign Up to like & get recommendations! 0
Related content
More Information
            
News
            
Social Media
            
Video
            
Recommended
               
Click one of the above tabs to view related content.